senior scientist - Medical Cell Biophysics Group
Richard B.M. Schasfoort (1959) graduated in 1984 as a biotechnology major from the University of Groningen. He defended his PhD thesis for a new approach to biosensor operation in 1989. He is founder of the company IBIS Technologies BV after selling his shares of Bio-intermediair BV in 1996. He developed at IBIS Technologies the Surface Plasmon Resonance imaging (SPRi) platform. In 2002, Richard started the Biochip group at the University of Twente after receiving the VIDI grant from NWO. He is co-author of > 100 peer reviewed papers and editor of the Handbook of Surface Plasmon Resonance (2008 and 2017). In the chair Medical Cell BioPhysics of Prof. Leon Terstappen, he investigates single cell binding and secretion fingerprinting of cancer cells. Since the Corona outbreak in March 2020, he changed his focus to antibody profiling using SPRi of patients with COVID19 and cooperates with the hospital Medical Spectrum Twente/Medlon.
Presence and strength of binding antibody profiles against SARS-CoV-2 during CoViD-19 infection.
Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 CoViD-19 patients. The high-throughput assay enables to follow the specific immune response of ultimate 384 individuals for these four parameters in one run. During the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels went down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The SPRi assay provides additional insights in the immune status of patients recovering from CoViD-19 and can be applied for the assessment of the immune reaction of healthy individuals in vaccination programs.